Q4 FY22 Earnings Presentation
Table of
Contents
Executive Portfolio Financial Guidance &
Summary Highlights Highlights Assumptions
ESG Appendix
Medical Surgical (continued)
MSD growth ex-vents despite Omicron-driven procedure and supply chain disruption
Respiratory, Gastrointestinal, & Renal (RGR)
Patient Monitoring
Flat
•
Strong pulse oximetry sensor growth driven by increased hospital admissions and use of monitoring
throughout the hospital
Decline in monitor sales due to strong hardware demand in prior year
Respiratory Interventions
Low-30s
Ventilator sales still above pre-COVID levels given Omicron wave, yet faced a tough comp as the
market continues to normalize
MCGRATH™ MAC video laryngoscope had LSD growth driven by an increase in blade volumes;
demonstrates further adoption for routine use
MSD
Gastrointestinal
MSD growth despite COVID-19 weighing on procedure volumes; key revenue contributions from
ManoScan TM, PillCam™M, and Emprint TM product lines
•
MSD
Announcing Health Equity program with Amazon Web Services and ASGE for colon cancer
screening, placing GI Genius TM modules in low income and underserved U.S. communities
Renal Care Solutions
•
Strong growth across acute therapies and renal access; in-line with market in chronic therapies
34%
Respiratory,
Gastrointestinal
& Renal
15 | Q3 FY22 earnings presentation | February 22, 2022
Emprint™ HP
Ablation system
Medical Surgical
66%
Surgical
Innovations
MedtronicView entire presentation